News

PET/MR beats PET/CT at imaging suspected occult tumors

PET/MR has proven more precise than PET/CT in a prospective study comparing the modalities on their in-practice utility for clarifying the workup of cancers of unknown primary origin, according to research published in Clinical Nuclear Medicine.

Tetsuro Sekine, MD, PhD, of the University of Zurich in Switzerland and Nippon Medical School in Japan and colleagues performed sequential PET/CT and PET/MR in 43 patients who were referred for suspected occult primary tumors. Read more.

Patients undergo PET/CT scans while using video goggles for distraction

Researchers at the Cincinnati Children’s Hospital Medical Center used video goggles to distract children undergoing PET or CT scans to determine whether they created CT and PET artifacts. Thirty non-sedated patients, aged four to 13 years old, watched videos of their choice using the goggles during whole-body PET/CT imaging. Half of the patients were tested using a scanner installed in 2006 and the other half with one from 2013. Read more.

3D printed kidney models help determine doses for nuclear medicine

Nuclear medicine, an area of medicine which involves the application of radioactive substances to the body, can be a crucial part of diagnosing and determining the seriousness of a patient’s disease. Predictably, however, the use of radioactive equipment also comes with certain risks. Radiation can be harmful to the body, so a crucial part of nuclear medicine has been to control and reduce the amount of radioactive materials that are injected into the body, whether orally or intravenously. And that’s where 3D printing comes into play: A team of researchers from the University of Würzburg in Germany has demonstrated how 3D printed organ models could have an important role in testing dosage amounts of radioactive materials for clinical prototyping. Read more.

New PET imaging agent detects metastatic prostate cancer

Researchers at Memorial Sloan Kettering Cancer Center demonstrated that a new PET imaging agent can detect metastatic prostate cancer in regions that it has previously been difficult to spot. Results from the Phase 1 dose-escalation study of Zr-89-deferrioxamine-IAB2M were published in the December 2016 issue of The Journal of Nuclear Medicine.

With an estimated 1.1 million new cases and over 300,000 deaths annually from prostate cancer, it is the second most common cancer among men globally, according to the World Health Organization. Read more.

About NMC  |  Products  |  Quote  |  News  |  Resources  |  Contact  |  Sitemap